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Abstract
Background: Onchocerciasis is endemic in 12 of the 14 health districts of Sierra Leone. Good treatment coverage
of community-directed treatment with ivermectin was achieved between 2005 and 2009 after the 11-year civil
conflict. Sentinel site surveys were conducted in 2010 to evaluate the impact of five annual rounds of ivermectin
distribution.
Methods: In total, 39 sentinel villages from hyper- and meso-endemic areas across the 12 endemic districts were
surveyed using skin snips in 2010. Results were analyzed and compared with the baseline data from the same 39
villages.
Results: The average microfilaridermia (MF) prevalence across 39 sentinel villages was 53.10% at baseline. The MF
prevalence was higher in older age groups, with the lowest in the age group of 1–9 years (11.00%) and the highest
in the age group of 40–49 years (82.31%). Overall mean MF density among the positives was 28.87 microfilariae
(mf)/snip, increasing with age with the lowest in the age group of 1–9 years and the highest in the age group of
40–49 years. Males had higher MF prevalence and density than females. In 2010 after five rounds of mass drug
administration, the overall MF prevalence decreased by 60.26% from 53.10% to 21.10%; the overall mean MF
density among the positives decreased by 71.29% from 28.87 mf/snip to 8.29 mf/snip; and the overall mean MF
density among all persons examined decreased by 88.58% from 15.33 mf/snip to 1.75 mf/snip. Ten of 12 endemic
districts had > 50% reduction in MF prevalence. Eleven of 12 districts had ≥50% reduction in mean MF density
among the positives.
Conclusions: A significant reduction of onchocerciasis MF prevalence and mean density was recorded in all 12
districts of Sierra Leone after five annual MDAs with effective treatment coverage. The results suggested that the
onchocerciasis elimination programme in Sierra Leone was on course to reach the objective of eliminating
onchocerciasis in the country by the year 2025. Annual MDA with ivermectin should continue in all 12 districts and
further evaluations are needed across the country to assist the NTDP with programme decision making.
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Background
Onchocerciasis, also known as river blindness or Robles’
disease, is a parasitic disease caused by infection with
the parasite Onchocerca volvulus. The disease is trans-
mitted to humans by the black fly (Simulium spp.) and
its pathology is linked to the death of the microfilariae
in the skin and eyes [1–3]. Humans are known as the
main reservoirs for O. volvulus [4]. Some animals such
as elands and buffalos are possible reservoir hosts, which
makes control of the disease in areas where these ani-
mals co-exist more difficult [5]. Currently, there are an
estimated 187 million people at risk of onchocerciasis
among which 37 million are infected with O. volvulus.
Among those infected, an estimated 4 million people live
with skin manifestations of the disease and 2 million are
estimated to be either visually impaired or blind [1–4].
Onchocerciasis is the world’s second leading infectious
cause of blindness after trachoma. Blindness from on-
chocerciasis occurs early in life (20–30 years old) and
therefore creates socio-economic problems for those af-
fected, their families and their communities [1–4].
About 99% of reported cases of the disease are in 31 en-
demic countries in sub-Saharan Africa [1, 3, 6–8].
Onchocerciasis control in Africa started with the
launching of the Onchocerciasis Control Programme in
West Africa (OCP) in seven countries (Benin, Burkina
Faso, Cote d’Ivoire, Ghana, Mali, Niger and Togo) in
1974 focusing on vector control and then continued
with the African Programme for Onchocerciasis Control
(APOC) in 1995 focusing on community-directed treat-
ment with ivermectin (CDTI) in meso- (microfilarider-
mia [MF] prevalence 40%–59.9%) and hyper- (MF
prevalence ≥60%) endemic sites [9]. Since 2009 there
has been a paradigm shift from control of onchocerciasis
as a public health problem (reduction of O. volvulus MF
prevalence to an acceptable low level where transmission
may continue) to elimination of the disease by stopping
local transmission. This shift was motivated by studies
in Senegal and Mali which demonstrated that through
treatment with ivermectin it was possible to eliminate
the disease [10]. It is currently believed that below 5% O.
volvulus MF prevalence the disease prevalence would
continue to drop even in the absence of treatment and
transmission would stop eventually [4, 10]. The recom-
mended programme coverage (i.e. proportion of people
ingesting ivermectin among people targeted in the en-
demic districts that are eligible for treatment, i.e.
≥5 years) during treatment with ivermectin is ≥80% in
all endemic areas [3, 4, 10–13].
The endemicity of onchocerciasis was demonstrated in
Sierra Leone in 1926 when Blacklock first described its
transmission through the black fly (S. damnosum) in the
Kono district [14]. Onchocerciasis control efforts in the
country started as early as in 1957 with insecticide treat-
ments along the Tonkolili River that was found to be the
most severely affected [15]. It was documented that on-
chocerciasis was the second most common cause of
blindness after cataracts in Sierra Leone and in the late
1980s the former OCP extended its activities to four
other countries - Guinea, Guinea-Bissau, Senegal and Si-
erra Leone [16–19]. Considerable work since the 1950s
demonstrated high onchocerciasis prevalence in Sierra
Leone along the main rivers and existence of black flies
in the entire country except in areas around the capital
of Freetown and the southern coastal plain of the
Bonthe district [20]. During 1988–2004, surveys from
177 sites across all 14 districts, selected based on prox-
imity to rivers and surveyed using the skin snip method,
showed that the unadjusted MF prevalence varied from
0% to 78.3% (see Fig. 1) [20]. With technical assistance
from APOC, villages around survey sites were classified
to be hypo-, meso- or hyper-endemic according to the
adjusted MF prevalence. The historical data and time-
lines of onchocerciasis control activities in Sierra Leone
is summarized in Table 1.
The National Onchocerciasis Control Programme
(NOCP) in Sierra Leone was established in 1989 under
the OCP. However, the civil conflict between 1991 and
2002 negatively impacted on onchocerciasis control ac-
tivities, and from 1997 to 2002 only limited onchocercia-
sis control activities were conducted in areas with high
prevalence and with security; therefore, treatment cover-
age before 2002 was deemed not reliable. With financial
and technical support from APOC, the NOCP restarted
interventions in 2003 through the Special Intervention
Zones (SIZ) programme (2003–2007). CDTI was imple-
mented in meso- and hyper-endemic areas in the 12 en-
demic districts [17–19, 21]. However, epidemiological
coverage (i.e. proportion of people ingesting ivermectin
among the total population in the targeted endemic dis-
tricts) was reported to be 36% and 28% in 2003 and
2004 respectively, and geographic coverage (i.e. propor-
tion of endemic communities and districts targeted
among all the endemic communities and districts need-
ing treatment) could not be determined for the two
years [20]. Efforts to control onchocerciasis improved in
2005, in part due to changes effected within the
programme management by the Ministry of Health and
Sanitation (MOHS) to improve onchocerciasis control
efforts in the country [20]. Treatment coverage has sig-
nificantly improved since 2005.
In 2007, the NOCP was expanded to become the na-
tional integrated Neglected Tropical Disease Programme
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(NTDP) to include onchocerciasis, lymphatic filariasis
(LF), schistosomiasis and soil-transmitted helminths. LF
was endemic in all 14 districts and co-endemic with on-
chocerciasis in 12 districts. Therefore, co-administering
albendazole and ivermectin in all LF endemic districts
effectively treated all hyper-, meso- and hypo-endemic
villages for onchocerciasis.
The current World Health Organisation (WHO) guide-
lines on onchocerciasis elimination recommend impact
assessment following 3–5 annual rounds of effective iver-
mectin distribution [22]. In line with these recommenda-
tions, a national sentinel site assessment was conducted in
2010–2011 using the skin snip method. The purpose of
this paper is to determine the impact of five annual
rounds of ivermectin distribution on the transmission of
onchocerciasis. We compared the data from sentinel sites
across the 12 onchocerciasis-endemic districts at baseline
and in 2010–2011 and discussed the way forward in
reaching onchocerciasis elimination in Sierra Leone.
Methods
Mass drug administration
Annual CDTI started in 2003. However, effective treat-
ment coverage was not achieved until 2005 due to un-
certainty around population data post-war and the
internal migration of displaced people. Integrated, an-
nual onchocerciasis/LF mass drug administration
(MDA) with ivermectin and albendazole was piloted in
2007 in six districts located in border areas with neigh-
bouring Guinea and Liberia, while CDTI continued in
the other six districts. Integrated onchocerciasis/LF
MDA was scaled up to cover all 12 coendemic districts
in 2008. Community-directed drug distributors (CDDs)
used dose poles to distribute ivermectin and later iver-
mectin plus albendazole to the eligible population aged
five years and older. The CDDs were literate members
of communities that were selected by their communi-
ties. District health workers conducted training of
CDDs for MDA and provided supervision during MDA.
Fig. 1 Distribution map of unadjusted point prevalence of onchocerciasis from baseline surveys in Sierra Leone. Data were collected during 1988
and 2004. Prevalence results from different years are plotted separately
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NTDP staff and members of the district health manage-
ment teams (DHMTs) also supported training and
supervision of the MDA.
Distribution of medicines was recorded using com-
munity registers. The register was designed to capture
all members of each community targeted for treat-
ment. Before each MDA, CDDs conducted pre-MDA
census and updated the community register to reflect
those that had left the community, those that had
joined the community and the newly born. MDA de-
tails were captured in the registers. After each MDA,
the details were summarised on village reporting
forms by CDDs and submitted to the supervising dis-
trict health workers, who in turn summarised and
submitted the reporting forms to include all villages
they covered to DHMTs. Each DHMT then submitted
the district summary report to the NTDP that col-
lated results from all districts.
Baseline surveys and sentinel sites
Baseline data were collected during 1988–2004 from 177
sites as illustrated in Fig. 1. The sites were randomly se-
lected from all 14 districts of Sierra Leone based on their
closeness to the ten major rivers and their tributaries
[20]. To monitor the impact on the onchocerciasis
prevalence and MF density after five rounds of MDA, 46
sites with high prevalence (MF prevalence ≥40%) from
the 177 baseline sites were selected as sentinel sites.
Seven of the 46 villages could not be located through
field visits and had to be dropped from the list. The dis-
appearance of villages was not unusual in the post-war
context as much displacement and migration had oc-
curred during the war. Accordingly, 39 sites (38 sites
with MF prevalence ≥40% and one site below 40%) in
the hyper- and meso-endemic areas were finally selected
as the sentinel sites and a cross-sectional survey was
conducted in 2010–11.
Table 1 Historical data and time lines of onchocerciasis control activities in Sierra Leone
Year Event Comments
1926 The endemicity of onchocerciasis was demonstrated in Sierra
Leone when Blacklock first described its transmission through
the black fly, S. damnosum in the Kono district
1957 Start of onchocerciasis control efforts with insecticide treatment
along the Tonkolili River that was found to be the most
severely affected
1974 Launch of the Onchocerciasis Control Programme in West
Africa (OCP) in 7 countries (Benin, Burkina Faso, Cote d’Ivoire,
Ghana, Mali, Niger and Togo)
Focus was on vector control but chemotherapy was added in
the late 1980s and early 2000s
1988/9 OCP was extended to four other countries - Guinea, Guinea-
Bissau, Senegal and Sierra Leone
1989 The National Onchocerciasis Control Program (NOCP) was
established in Sierra Leone under the OCP
1995 Launch of the African Programme for Onchocerciasis Control
(APOC)
Initiated the community-directed treatment with ivermectin
(CDTI) strategy
1991–2002 Civil conflict in Sierra Leone resulted in limited onchocerciasis
activities
Treatment coverage before 2002 are considered unreliable
2003 Onchocerciasis control activities was restarted as part of the
Special Intervention Zones (SIZ) programme (2003–2007) that
was managed by APOC
CDTI was implemented in meso- and hyper-endemic areas of
the 12 endemic districts with very poor epidemiological and
geographic coverage in 2003–2004
1998–2005 Epidemiological mapping was conducted with support from
APOC, showing high onchocerciasis prevalence along the main
rivers and existence of black flies in the entire country except in
areas around the capital Freetown and the southern coastal
plain of the Bonthe district
A total of 177 sites were surveyed using skin snip method
across 14 districts in the country.
2005 Management changes made within the NOCP by the Ministry
of Health and Sanitation (MOHS) to improve onchocerciasis
control efforts in the country
Better treatment coverage reported since then
2007 The NOCP expanded to become the national integrated
Neglected Tropical Disease Programme (NTDP) to include
onchocerciasis, lymphatic filariasis (LF), schistosomiasis and soil-
transmitted helminths. Trachoma was demonstrated to be non-
endemic in Sierra Leone.
Onchocerciasis and LF activities integrated since then in all 12
co-endemic districts by co-administering albendazole and iver-
mectin treating all hyper-, meso- and hypo-endemic villages
for onchocerciasis.
2009 Paradigm shift from control of onchocerciasis as a public health
problem (reduction of O. volvulus microfilaridermia prevalence
to an acceptable low level although transmission will continue)
to eliminating the disease by stopping local transmission
This was after studies in Senegal and Mali showed that
through treatment with ivermectin it is possible to eliminate
the disease
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Study population and parasitological detection
O. volvulus infection was determined in convenience
samples using the method of microscopic examination
of skin snips for the presence of O. volvulus microfilariae
according to WHO/APOC recommendations. Skin snips
were done in all selected villages 11–12 months after the
last MDA. All volunteers/participants aged one year or
above (at baseline) or five years and above (2010 survey)
in each site were eligible for inclusion in the study with-
out discrimination on gender, social status, religion or
ethnicity. They were asked for identification data, in-
cluding name, age, sex, occupation, and number of years
they were resident in the village. Two skin biopsies were
obtained from the right and left iliac crests of each par-
ticipant. A 2 mm Holth corneoscleral punch was used to
obtain the two bloodless skin snip biopsies. The scleral
punch was sterilised with sodium hypo-chlorite solution
and distilled water and then autoclaved for 15 min after
taking biopsies from each participant.
The samples were microscopically examined for the
presence of O. volvulus microfilariae after incubation for
30 min in distilled water. Negative skin snip samples
were then kept in saline solution for another 24 h and
microscopically re-examined. The number of microfilar-
iae was counted and expressed as the number of micro-
filariae per snip, and the results were recorded for each
person examined. For quality control, experts recruited
by OCP and later APOC that worked in the field with
the NOCP survey teams examined all positive slides and
10% of the negative slides.
Statistical analysis
Results were entered into MS Excel and analysed in
SPSS (IBM, Version 19, USA). Prevalence and density of
MF were calculated by district, sex and age group, and
were compared with the baseline data from the same 39
sites. The 95% confidence intervals (CIs) for prevalence
were calculated using the Wilson score method without
continuity correction [23]. The arithmetic mean MF
density of infection with 95% CI was calculated for the
total population examined (both positives and negatives)
and for the positives only. The Chi-squared test was
used to compare the differences in prevalence, and the
Kruskal-Wallis test was used to compare the differences
in MF density. Treatment coverage was calculated ac-
cording to the WHO guidelines and reported using two
indicators: epidemiological coverage and programme
coverage [24]. The total population used was the total
number of people registered during the pre-MDA census
CDDs conducted each year. The distribution map of the
unadjusted point prevalence of the 39 villages used as
sentinel sites were produced using ArcGIS software ver-
sion 10.4 (ESRI, Redlands, US) [25, 26].
Results
MDA results 2005–2009
In 2005–2007, ivermectin was distributed annually to a
total of 8451 villages that were meso- and hyper-
endemic for onchocerciasis, though about 50% of these
villages conducted integrated onchocerciasis/LF MDA
with ivermectin and albendazole in 2007. Between 2008
and 2009 ivermectin together with albendazole was dis-
tributed annually in the 12 provincial districts for treat-
ment of both LF and onchocerciasis. The treatment area
included the 8451 meso- and hyper-endemic onchocer-
ciasis villages that received prior CDTI as well as the
hypo-endemic villages that had not been treated under
CDTI. Geographic coverage for onchocerciasis treatment
of meso- and hyper-endemic communities in these dis-
tricts during this period was 100%. As described previ-
ously, treatment coverage in 2003 and 2004 was
ineffective and is not shown here. Table 2 shows treat-
ment coverage between 2005 and 2009. Except for 2005,
treatment coverage in other years for all districts was
above the minimum required threshold.
Onchocerciasis situation at baseline
MF prevalence
The results of surveys at baseline are shown in Table 3.
At baseline, a total of 7116 people were tested in all the
39 villages: 3461 (48.6%) males and 3655 (51.4%) fe-
males. Geographical locations of the 39 sentinel sites are
shown in Fig. 2. The average baseline MF prevalence
from the sentinel sites within each district varied from
39.01% (95% CI: 36.17–41.91%) to 61.94% (95% CI: 54.
09–69.20%). MF prevalence in the northern districts
(Kambia, Tonkolili, Koinadugu, Bombali and Port Loko)
tended to be higher than prevalence in the southern dis-
tricts (Moyamba, Bo, Pujehun and Bonthe), while the
prevalence in the eastern districts was relatively the low-
est (Kailahun, Kenema and Kono). The overall MF
prevalence among all 7116 participants was 53.09% (95%
CI: 51.93–54.25%). The MF prevalence was higher in
males (55.19%, 95% CI: 53.52–56.84%) than in females
(51.11%, 95% CI: 49.49–52.73%) (P < 0.001). Among dif-
ferent age groups, the MF prevalence was lowest in 1–
9 years (11.05%, 95% CI: 9.80–12.43%), increased sharply
to 50.57% (95% CI: 47.87–53.26%) in 10–19 years,
peaked at 82.31% (95% CI: 79.39–84.90%) in 40–49 years,
and then dropped to 76.17% (95% CI: 72.84–79.20%) in
60 years and aobve.
MF density
Among all 7116 people tested, the overall arithmetic
mean density (AMD-all) of MF was 15.33 microfilariae
(mf)/snip (95% CI: 14.43–16.24 mf/snip), 21.11 mf/snip
(95% CI: 19.49–22.72 mf/snip) in males and 9.94 mf/snip
(95% CI: 9.09–10.79 mf/snip) in females (P < 0.001).
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AMD-all ranged from 6.51 mf/snip (95% CI: 3.47–9.54
mf/snip) in Kenema district to 22.09 mf/snip (95% CI:
19.28–24.91 mf/snip) in Tonkolili district. Among the
3778 people that tested MF positive, the arithmetic
mean density (AMD-positive) was 28.87 mf/snip (95%
CI: 27.29–30.46 mf/snip), 38.16 mf/snip (95% CI: 35.47–
40.84 mf/snip) in males and 19.38 mf/snip (95% CI:
17.85–20.92 mf/snip) in females (P < 0.001). The AMD-
positive ranged from 14.42 mf/snip (95% CI: 7.91–20.94
mf/snip) in Kenema district to 37.48 mf/snip (95% CI:
31.36–43.60 mf/snip) in Kono district. There was no
trend observed for MF prevalence between the regions for
the AMD-all and AMD-positive.
The AMD-all was lowest among the age group of 1–
9 years (0.91 mf/snip, 95% CI: 0.51–1.30 mf/snip), in-
creased sharply to 6.91 mf/snip (95% CI: 5.92–7.91 mf/
snip) in the age group of 10–19 years, peaked at 35.94
mf/snip (95% CI: 31.44–40.44 mf/snip) in the age group
of 40–49 years, and then dropped to 21.58 mf/snip (95%
CI: 18.44–24.72 mf/snip) in the age group of ≥60 years.
The AMD-positive followed the same pattern as AMD-
all (Table 3).
Onchocerciasis situation in 2010
MF prevalence
In 2010, a total of 5621 people were tested in all the 39
villages: 2805 (49.9%) males and 2816 (50.1%) females.
The overall MF prevalence was 21.12% (95% CI: 20.07–
22.20%): 24.49% (95% CI: 22.94–26.12%) in males and
17.76% (95% CI: 16.39–19.21%) in females. Point MF
prevalence at each sentinel site showed a general trend
of decline in prevalence across the country from the
baseline, which was more evident in the northern part of
the country (Fig. 2). Compared with the baseline, overall
MF prevalence dropped by 60.22% (P < 0.001): 54.24%
among males (P < 0.001) and 64.12% among females
(P < 0.001). The MF prevalence among districts ranged
from 6.90% (95% CI: 2.71–16.43%) in Koinadugu district
to 29.96% (95% CI: 27.19–32.89%) in Moyamba district.
Reduction in MF prevalence among districts was, in gen-
eral, greater than 50% (P < 0.05), except for Bonthe and
Moyamba districts which had 34.25% (P < 0.01) and 48.52%
(P < 0.001) reductions in prevalence respectively.
Reductions in MF prevalence in Koinadugu and Pujehun
districts were both over 80% (P < 0.001). For the age
groups, the MF prevalence showed similar age pattern as at
the baseline but was at a significantly reduced level
(Table 3). Among the age groups, the highest reduction in
MF prevalence (82.55%) was recorded in 1–9 years
followed by the reduction in 10–19 years (66.40%).
MF density
The overall AMD-all was 1.75 mf/snip (95% CI: 1.48–2.02
mf/snip) and the AMD-positive was 8.29 mf/snip (95%
CI: 7.07–9.50 mf/snip), a significant drop of 88.58%
(P < 0.001) and 71.29% (P < 0.001) from the baseline,
Fig. 2 Unadjusted point prevalence of onchocerciasis at the 39 sentinel sites at baseline (1988–2004, on the left) and in 2010 (on the right).
Numbers represent the actual precentage point MF prevalence at each sentinel site
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respectively. Compared to the baseline, the AMD-all
was 2.55 mf/snip (95% CI: 2.04–3.06 mf/snip) in males,
a decrease of 87.92% (P < 0.001), and 0.96 mf/snip (95%
CI: 0.77–1.15 mf/snip) in females, a decrease of 90.34%
(P < 0.001). The AMD-positive was 10.40 mf/snip (95%
CI: 8.43–12.36 mf/snip) in males, a decrease of 72.75%
(P < 0.001) and 5.40 mf/snip (95% CI: 4.40–6.40mf/
snip) in females, a decrease of 72.14% (P < 0.001).
There was a significant difference in AMD between
males and females (P < 0.05). Among districts, the
AMD-all ranged from 0.05 mf/snip (95% CI: 0.00–0.11
mf/snip) in Koinadugu district to 3.10 mf/snip (95% CI:
1.80–4.40 mf/snip) in Port Loko district, in general a
significant reduction of > 70% (P < 0.05) across districts,
with the exception of Bonthe district, which showed a
reduction of 56.43% (P < 0.01). The AMD-positive
ranged from 0.75 mf/snip (95% CI: 0.00–1.55 mf/snip) in
Koinadugu district to 11.91 mf/snip (95% CI: 7.12–16.71
mf/snip) in Port Loko district, in general a significant re-
duction of > 50% (P < 0.05), with the exception of Bonthe
district where the reduction was 33.80% (P > 0.05). Among
the age groups, the AMD-all and AMD-positive showed
similar age distribution pattern as the baseline, however,
there was in general > 80% reduction for AMD-all
and > 60% reduction for AMD-positive (Table 3).
Discussion
The following distinct epidemiological patterns were de-
termined in the MF prevalence from the survey data: 1)
higher in males than in females, 2) lowest in 1–9 years
followed by that in 10–19 years, and 3) higher in the
northern districts than in the southern and eastern dis-
tricts. Distinct epidemiological patterns were also noted
in the MF density. AMD-all or AMD-positive was higher
in males than in females, was lowest among the age
group of 1–9 years followed by that in the age group of
10–19 years, and was highest among the age group of
40–49 years.
In general, males had higher O. volvulus infection
levels than females. Although MF prevalence in males
was only slightly higher than in females, the MF density
for all surveyed and positive-only participants was about
twice as high in males as in females. The similar male/
female differences in onchocerciasis prevalence, density
of infection and clinical disease have been discussed by
many authors [27–33]. However, it should be noted that
Gbakima and Sahr detected no difference in O. volvulus
infection between males and females in their Sierra
Leone study [34]. It has been suggested that higher O.
volvulus infection in males, compared to females, may
be due to increased exposure to black flies among males
through fishing and other activities that take place in
close proximity to rivers [29, 35, 36].
Lower age groups (1–9 years and 10–19 years) had the
lowest MF prevalence and density even within highly en-
demic areas. MF prevalence and density were highest in
the age group of 40–49 years. This age trend was similar
to the results of a study in Nigeria that found O. volvulus
MF prevalence and intensity increasing with age [28].
This may be explained by the fact that adults with grow-
ing age have more exposure to the bite of infected black
flies. It is reported that maternal O. volvulus infection
can be transmitted, even in utero, to their children and
that children of onchocerciasis-infected mothers are
more likely to be infected with onchocerciasis [37, 38].
The fact that females in our surveyed villages were less
infected than men suggests that children in these villages
may have had less exposure to the bite of infected black
flies or in utero transmission.
It has been suggested that the regional and district var-
iations of onchocerciasis prevalence at baseline could be
linked with vector ecology and density, which also de-
pend on the distance of villages studied from the river
basin and the geography of the river [39]. Previous stud-
ies in Sierra Leone showed that O. volvulus MF preva-
lence was higher in the forest (71.8%) than in Savannah
villages (51.9%) [30]. In general, the eastern region has
the forest strain of the O. volvulus parasite, characterised
by low intensity of infection, mild skin disease and rela-
tively low blindness rate; the southern region has a mix-
ture of forest and Savannah strains of the parasite,
characterised by high infection intensity, mild skin disease
and relatively higher blindness rate (sometimes higher
than blindness rates recorded in the Savannah area); and
the northern region has the Savannah strain of the para-
site, characterised by high infection intensity, mild skin
disease, and relatively high blindness rate [14, 34]. Our
survey data may have reflected these.
The 2010 evaluation revealed a significant decrease in
onchocerciasis MF prevalence and density in the same
39 sentinel villages after just five rounds of annual
MDA. The same epidemiological dynamics as the base-
line was observed in the 2010 evaluations, i.e. MF preva-
lence was higher in males than in females and MF
density was twice as high in males as in females. The re-
gional disease distribution observed at baseline (the north-
ern districts with relatively higher prevalence, followed by
the southern and then the eastern having the lowest rela-
tive prevalence) appeared to have changed significantly
after five years of MDA. In 2010, the northern districts
had the lowest average MF prevalence relative to the east-
ern and southern districts. This observation could not be
explained by differences in treatment coverage (similar in
all the regions) but may be due to the responsiveness of
different parasite strains to treatment and further studies
are needed to clarify this. The significant reduction in O.
volvulus infection after five years of MDA is similar to the
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results from other countries. In Cameroon, onchocerciasis
MF prevalence in the Fundong health district decreased
from 60.0% to 3.5% after six rounds of continuous MDA
using the CDTI strategy [40]. After seven years (1995–
2001) of ivermectin treatment in three endemic villages of
the Etung Local Government Area of Lower Cross River
Basin, Nigeria, MF prevalence decreased from 63.3% at
baseline to 39.3% and community MF density dropped
from 7.11 to 2.31 mf/snip [38].
Significant progress has been made on onchocerciasis
elimination in Sierra Leone. Effective epidemiological
and programme coverage in all endemic areas was
reached and has been maintained since 2005. By 2017,
considering the missed MDA due to Ebola virus disease
in 2014, a total of 10 rounds of effective MDA have been
completed. Per the current WHO recommendations,
12–15 years of MDA are needed for onchocerciasis
elimination [22]. It is anticipated that additional 2–5 an-
nual rounds of MDA may bring Sierra Leone to the
point of stopping MDA for onchocerciasis. However,
there are currently no guidelines on the prevalence
threshold and methodology for deciding when to move
to stop-MDA evaluation. While continuing with the
ivermectin MDA in the 12 districts, the NTDP has
established a national onchocerciasis elimination com-
mittee (NOEC), per WHO recommendations, which will
review the programme progress and recommend a way
forward for the NTDP on onchocerciasis elimination.
There are certain limitations in this study. First, the
baseline data were obtained over a long period. Some
villages were studied pre-war in 1988–1990 and others
were studied post-war in 2002–2004 with a gap of about
11 years. It is possible that the epidemiological situation
may have changed in villages studied in the earlier years.
This is exemplified by the fact that 7 of the originally se-
lected villages could not be traced. Therefore, comparing
with the baseline data collected pre-war, the reduction
in infection seen in 2010 may have not been entirely due
to the impact of MDA. However, we tried to minimize
this effect by including more villages with more recent
data (31 sites with data from 2002 to 2004 and eight
sites with data from 1998 to 1990). Villages with older
data (1988–1990) were only selected when more recent
data (2002–04) were not available for a district. Second,
in the 2010 evaluation, only persons aged five years and
above were studied while all persons aged over one year
old were studied at baseline. This resulted in fewer chil-
dren aged 1–9 years examined in the 2010 evaluation. The
decision not to study children below five years of age was
based on the high refusal rate to skin snip in this age group
observed in communities during the baseline studies.
Newly developed serological tools (OV16 rapid diagnostic
tests [RDTs] and OV16 ELISA) should be considered for
better compliance in future evaluations [41–43]. Third, the
sentinel sites surveyed in 2010 did not include hypo-
endemic villages. As the focus for onchocerciasis has
shifted from control to elimination and hypo-endemic vil-
lages have been treated through LF MDA. It is essential to
include hypo-endemic villages in future evaluations to have
a full picture of the current onchocerciasis for national
programme decision-making.
Conclusions
There was a significant reduction of onchocerciasis MF
prevalence and MF density across the 12 rural
onchocerciasis-endemic districts of Sierra Leone after
five annual MDAs. The results suggested that the on-
chocerciasis elimination programme in Sierra Leone
was on course to reach the objective of eliminating on-
chocerciasis in Sierra Leone by the year 2025. However,
MDA needs to continue in all 12 districts with required
treatment coverage to reach the goal of interrupting
transmission. Further evaluations across the country
are needed to assist the NTDP with programme
decision-making.
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